Cameron Turtle
Chief Executive Officer, Director at Spyre Therapeutics, Inc. (SYRE) since June 2023
Cameron Turtle has filed 23 insider reports with the SEC since January 2021, as chief Executive Officer and director at Spyre Therapeutics, Inc. (SYRE), director at Damora Therapeutics, Inc. (DMRA) and director at Oruka Therapeutics, Inc. (ORKA) and at 1 more company. In the last 12 months Cameron Turtle sold $10.3M of stock on the open market. In the latest filing, on October 3, 2026, Cameron Turtle sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) for $1.38M at an average of $92.01.
- Filings
- 23
- Companies
- 4
- Bought on market
- None
- Sold on market
- $11.4M
Companies where Cameron Turtle is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Executive Officer, Directorsince June 2023 | 537,540 | $11.4M | $93.81 | Oct 3, 2026 | |||
| Directorsince March 2026 | $22.56 | Mar 25, 2026 | |||||
| Directorsince August 2024 | $96.32 | Jun 3, 2025 | |||||
| Officer | 0 | Jan 29, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Oct 1, 2026-$1.38MSYREChief Executive Officer Turtle Cameron sold $1,380,105 worth of shares (15,000 units at $92.01) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 537,540 unitsForm 4Open-market sale10b5-1 plan
- Sep 1, 2026-$1.31MSYREChief Executive Officer Turtle Cameron sold $1,309,410 worth of shares (15,000 units at $87.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 552,540 unitsForm 4Open-market sale10b5-1 plan
- Aug 3, 2026-$1.43MSYREChief Executive Officer Turtle Cameron sold $1,432,705 worth of shares (15,000 units at $95.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 567,540 unitsForm 4Open-market sale10b5-1 plan
- Jul 1, 2026-$1.32MSYREChief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 unitsForm 4Open-market sale10b5-1 plan
- Jun 1, 2026-$1.06MSYREChief Executive Officer Turtle Cameron sold $1,056,486 worth of shares (15,000 units at $70.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 597,540 unitsForm 4Open-market sale10b5-1 plan
- May 1, 2026-$1.07MSYREChief Executive Officer Turtle Cameron sold $1,070,507 worth of shares (15,000 units at $71.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 612,540 unitsForm 4Open-market sale10b5-1 plan
- Apr 1, 2026-$740KSYRESEC Form 4 filed by Turtle CameronForm 4Open-market sale10b5-1 plan
- Mar 23, 2026DMRASEC Form 4 filed by Turtle CameronForm 4Grant or award
- Mar 23, 2026DMRACameron Turtle became an insiderForm 3New insider
- Mar 2, 2026-$633KSYREChief Executive Officer Turtle Cameron sold $632,866 worth of shares (15,000 units at $42.19), decreasing direct ownership by 2% to 642,540 unitsForm 4Open-market sale10b5-1 plan
- Feb 2, 2026-$492KSYREChief Executive Officer Turtle Cameron sold $492,045 worth of shares (15,000 units at $32.80), decreasing direct ownership by 2% to 657,540 unitsForm 4Open-market sale10b5-1 plan
- Jan 9, 2026SYRESEC Form 4 filed by Chief Executive Officer Turtle CameronForm 4Grant or award
- Jan 2, 2026-$460KSYREChief Executive Officer Turtle Cameron sold $460,134 worth of shares (15,000 units at $30.68), decreasing direct ownership by 2% to 671,907 unitsForm 4Open-market sale10b5-1 plan
- Dec 1, 2025-$435KSYREChief Executive Officer Turtle Cameron sold $435,356 worth of shares (15,000 units at $29.02), decreasing direct ownership by 2% to 686,907 unitsForm 4Open-market sale10b5-1 plan
- Nov 3, 2025-$1.05MSYREChief Executive Officer Turtle Cameron sold $1,049,778 worth of shares (45,000 units at $23.33), decreasing direct ownership by 6% to 701,907 unitsForm 4Open-market sale10b5-1 plan
- Jun 2, 2025ORKASEC Form 4 filed by Director Turtle CameronForm 4Grant or award
- Jan 15, 2025SYRESEC Form 4 filed by Chief Executive Officer Turtle CameronForm 4Grant or award
- Aug 29, 2024ORKANew insider Turtle Cameron claimed ownership of 85,233 sharesForm 3New insider
- Feb 15, 2024SYRETurtle Cameron was granted 400 shares, increasing direct ownership by 0.05% to 746,907 unitsForm 4Grant or award
- Feb 1, 2024SYRESEC Form 4 filed by Turtle CameronForm 4Grant or award
- Nov 24, 2023SYRETurtle Cameron converted options into 723,440 shares, increasing direct ownership by 3,136% to 746,507 unitsForm 4Grant or awardConversion of a derivative
- Jun 22, 2023SYRESEC Form 3: New insider Turtle Cameron claimed ownership of 576,699 sharesForm 3New insider
- Jan 26, 2021EIDXSEC Form 4: Cameron Turtle decreased ownership by 100% to 0 unitsForm 4Sale back to the companyTender of shares in a change of control
Compare Cameron Turtle with
- Cameron Turtle vs Joana Goncalves1 shared
- Cameron Turtle vs Arjun Agarwal1 shared
- Cameron Turtle vs Kristine M Ball1 shared
- Cameron Turtle vs Lawrence Otto Klein1 shared
- Cameron Turtle vs Heidy King-Jones1 shared
- Cameron Turtle vs Scott L Burrows1 shared
Other insiders at the same companies
- Joana GoncalvesORKA
- Arjun AgarwalORKA
- Kristine M BallORKA
- Lawrence Otto KleinORKA
- Heidy King-JonesSYRE
- Scott L BurrowsSYRE
- Jennifer JarrettDMRA
- Paul T QuinlanORKA
- Laura Lee SandlerORKA
- Larry Todd EdwardsORKA
- Andrew ChengDMRA
- Jeffrey W. AlbersSYRE
- Garrett WinslowDMRA
- Sheldon SloanSYRE
- Fairmount Funds Management LLCSYRE
- Michael Thomas HendersonSYRE
Questions about Cameron Turtle
- What is Cameron Turtle's role at Spyre Therapeutics, Inc.?
- Cameron Turtle reports to the SEC as chief Executive Officer and director at Spyre Therapeutics, Inc. (SYRE), according to the latest filing on October 3, 2026. Cameron Turtle has also filed as director at Damora Therapeutics, Inc. (DMRA), director at Oruka Therapeutics, Inc. (ORKA) and officer at Eidos Therapeutics, Inc. (EIDX).
- How many shares does Cameron Turtle own?
- After the latest filing that states it, Cameron Turtle directly owned 537,540 shares of Spyre Therapeutics, Inc. (SYRE). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Cameron Turtle bought or sold stock recently?
- The most recent open-market sale was on October 1, 2026: sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) for $1.38M at an average of $92.01.
- How do I get alerts when Cameron Turtle files?
- Follow Cameron Turtle on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Cameron Turtle filed 2 times in the last 90 days.
From SEC Forms 3, 4, 5 and 144 filed by Cameron Turtle (SEC CIK 0001758363). Totals count each trade once, skipping amendments whose original is on file, from Jan 29, 2021 on. View on SEC EDGAR